{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:52:35Z","timestamp":1788555155373,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Weight gain has been associated with the use of antiretrovirals in people with HIV, especially with integrase inhibitors or tenofovir alafenamide, and among women. In 2018, doravirine became the latest non-nucleoside reverse transcriptase inhibitor to be approved in the US. We assessed changes in weight over time among virologically suppressed individuals who switched to a regimen containing doravirine (DOR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From the US-based OPERA cohort, treatment-experienced adults with HIV who switched to a DOR-containing regimen between 30AUG2018-30NOV2022 with a viral load\u2009&lt;\u200950 copies\/mL were included (followed through 31MAY2023). The study population was characterized and a linear mixed model was used to estimate rates of weight change on DOR. Results were stratified by sex, by patterns of efavirenz (EFV) and\/or tenofovir disoproxil fumarate (TDF) use before\/after switch to DOR, and by integrase inhibitor (INSTI) &amp; tenofovir alafenamide (TAF) use combination (restricted to individuals who maintained the same combination before\/after switch).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 388 included individuals, 21% were women, 33% were Black, and 78% were obese or overweight at DOR switch. Overall, people who switched to DOR lost an average of 0.80\u00a0kg\/year (95% CI: -1.32, -0.28). Both women and men experienced statistically significant weight loss; women (70% Black, 70% aged\u2009\u2265\u200940 years) lost weight at a rate of -1.67\u00a0kg\/year (95% CI: -3.32, -0.02) and men at a rate of -0.60\u00a0kg\/year (95% CI: -1.12, -0.08). When EFV and TDF were absent before and after switch to DOR, statistically significant weight loss was observed. Among those who had the same INSTI and TAF combination throughout and had any INSTI or TAF use, a statistically non-significant trend toward weight loss was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In one of the first real-world analyses of weight changes among virologically suppressed individuals who switched to a DOR-containing regimen in the US, DOR was associated with statistically significant weight loss. Patterns of use of other antiretrovirals did not fully explain the observed weight loss. These findings are clinically meaningful given that most individuals included were overweight or obese at switch to DOR and that women were predominantly of perimenopausal or menopausal age.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12981-025-00761-5","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T13:12:40Z","timestamp":1750511560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Weight loss with real-world doravirine use in the OPERA cohort: a US-based cohort study"],"prefix":"10.1186","volume":"22","author":[{"given":"Karam","family":"Mounzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sension","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricky K.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Osterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohance O.","family":"Whiteside","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory P.","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"key":"761_CR1","unstructured":"UNAIDS. UNAIDS Data. 2021. Geneva: Joint United Nations Programme on HIV\/AIDS (UNAIDS); 2021. Contract No.: Licence: CC BY-NC-SA 3.0 IGO."},{"key":"761_CR2","doi-asserted-by":"crossref","unstructured":"Kanters S, Renaud F, Rangaraj A, Zhang K, Limbrick-Oldfield E, Hughes M et al. Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysis. eClinicalMedicine. 2022;48.","DOI":"10.1016\/j.eclinm.2022.101412"},{"issue":"5","key":"761_CR3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/QAI.0000000000001525","volume":"76","author":"J Norwood","year":"2017","unstructured":"Norwood J, Turner M, Bofill C, Rebeiro P, Shepherd B, Bebawy S, et al. Brief report: weight gain in persons with HIV switched from Efavirenz-Based to integrase strand transfer Inhibitor-Based regimens. J Acquir Immune Defic Syndr. 2017;76(5):527\u201331.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"761_CR4","doi-asserted-by":"crossref","unstructured":"Surial B, Mugglin C, Calmy A, Cavassini M, Gunthard HF, Stockle M et al. Weight and metabolic changes after switching from Tenofovir disoproxil fumarate to Tenofovir Alafenamide in people living with HIV: A cohort study. Ann Intern Med. 2021.","DOI":"10.7326\/M20-4853"},{"key":"761_CR5","doi-asserted-by":"crossref","unstructured":"Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2019.","DOI":"10.1093\/cid\/ciz999"},{"issue":"9","key":"761_CR6","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1089\/jwh.2017.6717","volume":"27","author":"SH Bares","year":"2018","unstructured":"Bares SH, Smeaton LM, Xu A, Godfrey C, McComsey GA. HIV-Infected women gain more weight than HIV-Infected men following the initiation of antiretroviral therapy. J Women\u2019s Health. 2018;27(9):1162\u20139.","journal-title":"J Women\u2019s Health"},{"issue":"suppl1","key":"761_CR7","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.1093\/ofid\/ofy210.547","volume":"5","author":"R Bedimo","year":"2018","unstructured":"Bedimo R, Adams-Huet B, Taylor BS, Lake J, Luque A. 538. Integrase Inhibitor-Based HAART is associated with greater BMI gains in blacks, hispanics, and women. Open Forum Infect Dis. 2018;5(suppl1):S199\u2013S.","journal-title":"Open Forum Infect Dis"},{"key":"761_CR8","doi-asserted-by":"crossref","unstructured":"Lake JE, Wu K, Bares SH, Debroy P, Godfrey C, Koethe JR et al. Risk factors for weight gain following switch to integrase Inhibitor-Based antiretroviral therapy. Clin Infect Dis. 2020.","DOI":"10.1093\/cid\/ciaa177"},{"issue":"2","key":"761_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/QAD.0000000000002742","volume":"35","author":"L Hamzah","year":"2021","unstructured":"Hamzah L, Post FA. Effect of menopause on weight gain, insulin and waist circumference in women with HIV who switch antiretroviral therapy to abacavir\/lamivudine\/dolutegravir. Aids. 2021;35(2):349\u201351.","journal-title":"Aids"},{"key":"761_CR10","doi-asserted-by":"crossref","unstructured":"Greendale GA, Sternfeld B, Huang M, Han W, Karvonen-Gutierrez C, Ruppert K et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5).","DOI":"10.1172\/jci.insight.124865"},{"key":"761_CR11","doi-asserted-by":"crossref","unstructured":"Abelman RA, Ma Y, Mehta CC, Yang Q, Xia F, Brock JB, et al. Switch to integrase strand transfer inhibitors during the menopausal transition is associated with accelerated body composition change in women with human immunodeficiency virus. Clinical Infectious Diseases; 2024.","DOI":"10.1093\/cid\/ciae540"},{"issue":"1","key":"761_CR12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1177\/1060028019869641","volume":"54","author":"SR Blevins","year":"2020","unstructured":"Blevins SR, Hester EK, Chastain DB, Cluck DB, Doravirine. A return of the NNRTI class?? Ann Pharmacother. 2020;54(1):64\u201374.","journal-title":"Ann Pharmacother"},{"key":"761_CR13","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV Department of Health and Human Services2021 [updated June 3, 2021. Available from: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf"},{"issue":"1","key":"761_CR14","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/S2352-3018(19)30336-4","volume":"7","author":"J-M Molina","year":"2020","unstructured":"Molina J-M, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, et al. Doravirine versus ritonavir-boosted Darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. Lancet HIV. 2020;7(1):e16\u201326.","journal-title":"Lancet HIV"},{"issue":"4","key":"761_CR15","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/QAI.0000000000002056","volume":"81","author":"M Johnson","year":"2019","unstructured":"Johnson M, Kumar P, Molina J-M, Rizzardini G, Cahn P, Bickel M, et al. Switching to doravirine\/lamivudine\/tenofovir disoproxil fumarate (DOR\/3TC\/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial. J Acquir Immune Defic Syndr. 2019;81(4):463\u201372.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"761_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/cid\/ciaa822","volume":"73","author":"C Orkin","year":"2020","unstructured":"Orkin C, Squires KE, Molina J-M, Sax PE, Sussmann O, Lin G, et al. Doravirine\/Lamivudine\/Tenofovir disoproxil fumarate (TDF) versus efavirenz\/emtricitabine\/tdf in Treatment-naive adults with human immunodeficiency virus type 1 infection: week 96 results of the randomized, Double-blind, phase 3 DRIVE-AHEAD noninferiority trial. Clin Infect Dis. 2020;73(1):33\u201342.","journal-title":"Clin Infect Dis"},{"key":"761_CR17","first-page":"201","volume":"12","author":"AE Rock","year":"2020","unstructured":"Rock AE, Lerner J, Badowski ME. Doravirine and its potential in the treatment of HIV: an Evidence-Based review of the emerging data. HIV AIDS (Auckl). 2020;12:201\u201310.","journal-title":"HIV AIDS (Auckl)"},{"key":"761_CR18","unstructured":"Centers for Disease Control and Prevention. HIV, Surveillance Report. vol. 34: Diagnoses of HIV Infection in the United States and Dependent Areas, 2021 2023 [updated 23 May 2023. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/149071"},{"key":"761_CR19","first-page":"252","volume":"11","author":"C Fryar","year":"2012","unstructured":"Fryar C, Gu Q, Ogden C. Anthropometric reference data for children and adults: united states, 2007\u20132010. Natl Cent Health Stat Vital Health Stat. 2012;11:252.","journal-title":"Natl Cent Health Stat Vital Health Stat"},{"issue":"2","key":"761_CR20","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1097\/QAI.0000000000002642","volume":"87","author":"P Kumar","year":"2021","unstructured":"Kumar P, Johnson M, Molina J-M, Rizzardini G, Cahn P, Bickel M, et al. Brief report: switching to DOR\/3TC\/TDF maintains HIV-1 virologic suppression through week 144 in the DRIVE-SHIFT trial. JAIDS J Acquir Immune Defic Syndr. 2021;87(2):801\u20135.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"761_CR21","unstructured":"Fox M, Mills AM, Ramgopal M, Bettacchi CJ, Osiyemi O, Hinestrosa F, et al. editors. Switch to DOR\/ISL (100\/0.25\u00a0mg) QD From BIC\/FTC\/TAF: A Blinded Phase III Study in Adults With HIV-1. Conference on Retroviruses and Opportunitic Infections; 2025; San Francisco, CA, USA."},{"key":"761_CR22","unstructured":"Fox M, Mngqibisa R, Velez JD, Kumar P, Braun DL, Carr A, et al. editors. Switch to DOR\/ISL (100\/0.25\u00a0mg) QD From Oral ART: An Open-Label Phase III Study in Adults With HIV-1. Conference on Retroviruses and Opportunistic Infections; 2025; San Francisco, CA, USA."},{"key":"761_CR23","doi-asserted-by":"crossref","unstructured":"Wohl DA, Koethe JR, Sax PE, McComsey GA, Kuritzkes DR, Moyle G et al. Antiretrovirals and weight change: weighing the evidence. Clin Infect Dis. 2024:ciae191.","DOI":"10.1093\/cid\/ciae191"},{"issue":"1","key":"761_CR24","doi-asserted-by":"publisher","first-page":"2339576","DOI":"10.1080\/25787489.2024.2339576","volume":"25","author":"AE Kousari","year":"2024","unstructured":"Kousari AE, Wilson MP, Hawkins KL, Bandali MM, Henao-Mart\u00ednez AF, Gardner EM, et al. Weight change with antiretroviral switch from integrase inhibitor or Tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV. HIV Res Clin Pract. 2024;25(1):2339576.","journal-title":"HIV Res Clin Pract"},{"issue":"30","key":"761_CR25","doi-asserted-by":"publisher","first-page":"e29855","DOI":"10.1097\/MD.0000000000029855","volume":"101","author":"M Mazzitelli","year":"2022","unstructured":"Mazzitelli M, Antoni MD, Castelli F, Ripamonti D, Zuglian G, Lapadula G, et al. Real-life use of doravirine in treatment-experienced people living with HIV: A multicenter Italian study. Med (Baltim). 2022;101(30):e29855.","journal-title":"Med (Baltim)"},{"issue":"14","key":"761_CR26","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1177\/09564624231195084","volume":"34","author":"L Calza","year":"2023","unstructured":"Calza L, Colangeli V, Pensalfine G, Appolloni L, Vitale S, Bon I, et al. Doravirine\/lamivudine\/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: A real-life experience. Int J STD AIDS. 2023;34(14):1018\u201323.","journal-title":"Int J STD AIDS"},{"issue":"1","key":"761_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/hiv.13711","volume":"26","author":"J Woods","year":"2025","unstructured":"Woods J, Sokhela S, Akpomiemie G, Bosch B, M\u00f6ller K, Bhaskar E, et al. DORA: 48-week weight and metabolic changes in black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy. HIV Med. 2025;26(1):81\u201396.","journal-title":"HIV Med"},{"key":"761_CR28","doi-asserted-by":"crossref","unstructured":"Woods J, Sokhela S, Akpomiemie G, Bosch B, M\u00f6ller K, Bhaskar E et al. DORA: 48-week weight and metabolic changes in black women with HIV, in a phase IIIb switch study from dolutegravir\u2010or efavirenz\u2010to doravirine\u2010based first\u2010line antiretroviral therapy. HIV Med. 2024.","DOI":"10.1111\/hiv.13711"},{"issue":"1","key":"761_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.24875\/AIDSRev.22000026","volume":"25","author":"E Dupont","year":"2023","unstructured":"Dupont E, Yombi JC. Antiretroviral therapy and weight gain in antiretroviral treatment-experienced HIV patients: A review. AIDS Rev. 2023;25(1):54\u201364.","journal-title":"AIDS Rev"},{"key":"761_CR30","doi-asserted-by":"crossref","unstructured":"Abelman RA, Nguyen TTJ, Ma Y, Bacchetti P, Messerlian G, French AL et al. Body composition changes over the menopausal transition in women with and without human immunodeficiency virus. Clin Infect Dis. 2023:ciad165.","DOI":"10.1093\/cid\/ciad165"},{"issue":"4","key":"761_CR31","doi-asserted-by":"publisher","first-page":"e25702","DOI":"10.1002\/jia2.25702","volume":"24","author":"PW Mallon","year":"2021","unstructured":"Mallon PW, Brunet L, Hsu RK, Fusco JS, Mounzer KC, Prajapati G, et al. Weight gain before and after switch from TDF to TAF in a U.S. Cohort study. J Int AIDS Soc. 2021;24(4):e25702.","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"761_CR32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/COH.0000000000000680","volume":"16","author":"JE Lake","year":"2021","unstructured":"Lake JE, Trevillyan J. Impact of integrase inhibitors and Tenofovir Alafenamide on weight gain in people with HIV. Curr Opin HIV AIDS. 2021;16(3):148\u201351.","journal-title":"Curr Opin HIV AIDS"},{"issue":"4","key":"761_CR33","doi-asserted-by":"publisher","first-page":"e25484","DOI":"10.1002\/jia2.25484","volume":"23","author":"K Bourgi","year":"2020","unstructured":"Bourgi K, Jenkins CA, Rebeiro PF, Palella F, Moore RD, Altoff KN, et al. Weight gain among treatment-na\u00efve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the united States and Canada. J Int AIDS Soc. 2020;23(4):e25484.","journal-title":"J Int AIDS Soc"},{"issue":"12","key":"761_CR34","doi-asserted-by":"publisher","first-page":"ofab537","DOI":"10.1093\/ofid\/ofab537","volume":"8","author":"EM Kileel","year":"2021","unstructured":"Kileel EM, Lo J, Malvestutto C, Fitch KV, Zanni MV, Fichtenbaum CJ, et al. Assessment of obesity and cardiometabolic status by integrase inhibitor use in REPRIEVE: A Propensity-Weighted analysis of a multinational primary cardiovascular prevention cohort of people with human immunodeficiency virus. Open Forum Infect Dis. 2021;8(12):ofab537.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"761_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/QAD.0000000000002725","volume":"35","author":"C Orkin","year":"2021","unstructured":"Orkin C, Elion R, Thompson M, Rockstroh JK, Alvarez Bognar F, Xu ZJ, et al. Changes in weight and BMI with first-line doravirine-based therapy. AIDS. 2021;35(1):91\u20139.","journal-title":"AIDS"},{"issue":"11","key":"761_CR36","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1016\/S2352-3018(21)00163-6","volume":"8","author":"L Bansi-Matharu","year":"2021","unstructured":"Bansi-Matharu L, Phillips A, Oprea C, Grabmeier-Pfistershammer K, G\u00fcnthard HF, De Wit S, et al. Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium. Lancet HIV. 2021;8(11):e711\u201322.","journal-title":"Lancet HIV"},{"issue":"4","key":"761_CR37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/hiv.12294","volume":"17","author":"AC Achhra","year":"2016","unstructured":"Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, et al. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med. 2016;17(4):255\u201368.","journal-title":"HIV Med"},{"issue":"12","key":"761_CR38","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1093\/cid\/civ192","volume":"60","author":"B Yuh","year":"2015","unstructured":"Yuh B, Tate J, Butt AA, Crothers K, Freiberg M, Leaf D, et al. Weight change after antiretroviral therapy and mortality. Clin Infect Dis. 2015;60(12):1852\u20139.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"761_CR39","doi-asserted-by":"publisher","first-page":"106737","DOI":"10.1016\/j.ijantimicag.2023.106737","volume":"61","author":"F Saladini","year":"2023","unstructured":"Saladini F, Giammarino F, Maggiolo F, Ferrara M, Cenderello G, Celesia BM, et al. Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO registry. Int J Antimicrob Agents. 2023;61(3):106737.","journal-title":"Int J Antimicrob Agents"},{"key":"761_CR40","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.7573\/dic.2021-9-1","volume":"11","author":"S Spivack","year":"2022","unstructured":"Spivack S, Pagkalinawan S, Samuel R, Koren DE. HIV: how to manage heavily treatment-experienced patients. Drugs Context. 2022;11:2021\u20139.","journal-title":"Drugs Context"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00761-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-025-00761-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00761-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T13:12:43Z","timestamp":1750511563000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-025-00761-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["761"],"URL":"https:\/\/doi.org\/10.1186\/s12981-025-00761-5","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional review board (IRB) approval covering patient data contained in the OPERA database was received from Advarra IRB; a waiver of informed consent and authorization for the use of protected health information for patient data was granted (Pro00023648). The study was conducted in accordance with HIPAA and HITECH requirements, which expand upon the ethical principles detailed in the 1964 Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KM has received research grants from Gilead Sciences, Merck, Janssen, and GSK\/ViiV Healthcare and honoraria for Speakers Bureau and Advisory Boards from Gilead Sciences, Merck, Janssen and GSK\/ViiV Healthcare; and advisory board participation with Epividian. LB, MDO, JSF, and GPF are employed by Epividian, Inc.; Epividian has had research funded by AIDS Healthcare Foundation, EMD Serono, Gilead Sciences, Janssen Scientific Affairs, LLC, Merck & Co., Theratechnologies Inc., and ViiV Healthcare. MS is on the Speakers Bureau for ViiV Healthcare and Gilead Sciences, and on the advisory board for ViiV Healthcare and Epividian. RKH has received research grants from Gilead Sciences, Janssen, and ViiV Healthcare, speaker honoraria from ViiV Healthcare, Merck, Gilead Sciences, and Janssen, and advisory board participation with ViiV Healthcare, Gilead Sciences, Janssen, and Epividian. YOW is employed by Merck & Co., Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"\u00b5l Microliter.3TC Lamivudine.AIDS Acquired immunodeficiency syndrome.ARV Antiretroviral.BMI Body mass index.CI Confidence interval.dL Deciliter.DOR Doravirine.EFV Efavirenz.eGFR Estimated glomerular filtration rate.FDA Food and Drug Administration.HIPAA Health Insurance Portability and Accountability Act.HITECH Health Information Technology for Economic and Clinical Health.HIV Human immunodeficiency virus.INSTI Integrase strand transfer inhibitor.IQR Interquartile range.IRB Institutional Review Board.kg Kilogram.N Number.NNRTI Non-nucleoside reverse transcriptase inhibitor.NRTI Nucleoside reverse transcriptase inhibitor.OPERA Observational Pharmaco-Epidemiology Research and Analysis.PI Protease inhibitor.TAF Tenofovir alafenamide.TDF Tenofovir disoproxil fumarate.US United States.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Abbreviations"}}],"article-number":"64"}}